Otorlaryngology Department, Affiliated Center Hospital of Shenyang Medical College, Shenyang, Liaoning, People's Republic of China.
Otorhinolarynology, China Medical University, Shengjing Hospital, Shenyang, Liaoning, People's Republic of China.
Cancer Control. 2020 Jan-Dec;27(1):1073274820902264. doi: 10.1177/1073274820902264.
This survey was conducted to determine the head and neck cancer (HNC) treatment strategies followed by oncologists in Chinese hospitals. It was a questionnaire-based survey, conducted from October 2017 to January 2018 in 100 random tertiary hospitals in 21 cities of China to elicit information from oncologists on the management practices for treating HNC in China. A validated, structured questionnaire was used for formal investigation with oncologists. The questions regarding HNC types, treatment strategies used for locally advanced head and neck cancer (LA HNC) and recurrent/metastatic head and neck cancer (r/m HNC), diagnosis and prognostic factors were included. The results were presented as percentages. Among the 272 oncologists, 93.4% were from tertiary care hospitals, with 35.3% and 36.4% patients from radiotherapy (RT) and oncology department, respectively. Nasopharyngeal carcinoma was the most commonly treated type of HNC according to 65.1% oncologists. Patients aged >75 years have worse prognosis and 65% oncologists corroborated that age of the patients influences treatment decision. Most of the oncologists (77.6%) preferred chemotherapy (CT) + anti-epidermal growth factor receptor targeted therapy as the first-line therapy for r/m HNC. Approximately 95% of oncologists considered induction chemotherapy (ICT) to retain organ functions and tumor shrinkage and 43.4% preferred ICT followed by chemoradiotherapy or ICT combined with RT followed by targeted therapy for LA HNC. For the management of HNC, Chinese oncologists recommended ICT with RT and targeted therapy for LA HNC and CT regimen combined with targeted therapy for r/m HNC.
这项调查旨在确定中国医院肿瘤学家采用的头颈部癌症（HNC）治疗策略。这是一项基于问卷调查的研究，于 2017 年 10 月至 2018 年 1 月在中国 21 个城市的 100 家随机三甲医院进行，旨在从肿瘤学家那里获取有关中国 HNC 治疗管理实践的信息。采用经过验证的结构化问卷对肿瘤学家进行正式调查。问卷内容包括 HNC 类型、局部晚期头颈部癌症（LA HNC）和复发性/转移性头颈部癌症（r/m HNC）的治疗策略、诊断和预后因素。结果以百分比表示。在 272 名肿瘤学家中，93.4%来自三级医院，其中 35.3%和 36.4%的患者分别来自放疗科和肿瘤科。65.1%的肿瘤学家认为鼻咽癌是最常见的 HNC 类型。年龄>75 岁的患者预后较差，65%的肿瘤学家认为患者年龄会影响治疗决策。大多数肿瘤学家（77.6%）首选化疗（CT）+抗表皮生长因子受体靶向治疗作为 r/m HNC 的一线治疗。约 95%的肿瘤学家认为诱导化疗（ICT）可以保留器官功能和肿瘤缩小，43.4%的肿瘤学家更喜欢 ICT 后行放化疗或 ICT 联合放疗后行靶向治疗用于 LA HNC。对于 HNC 的管理，中国肿瘤学家推荐 ICT 联合放疗和靶向治疗用于 LA HNC，CT 方案联合靶向治疗用于 r/m HNC。
